Therapyte’s Post

It should come as no surprise that Real-World Evidence has been named ISPOR's #1 trend for 2024. Beyond the traditional confines of randomized controlled trials, RWE studies are increasingly recognized for their speed and practicality in evaluating the safety and effectiveness of healthcare interventions across diverse patient populations. #rwe #realworldevidence #rwd #realworlddata #heor #clinicalresearch #clinicaltrials https://lnkd.in/eYHeT-w4

How do you improve health equity and diversity in pharmaceutical research?

RWD and RWE have many advantages for organisations that leverage them to their full potential, but also some disadvantages. One of the biggest drawbacks is the varying acceptance of RWE as “legit” evidence due to the role of unmeasured confounders. In the fall of 2022, PhRMA and BIO conducted a workshop on the subject of unmeasured confounders. A report that captures the main themes and learnings from the workshop has just been published and includes a discussion of novel methodologies for addressing the issue. One of the most interesting aspects of the report is the discussion around fit-for-purpose, research-grade RWD that needs to be intensively curated before being transformed into high-quality, trustworthy evidence generation (pages 11-12 in the report). At Cegedim Health Data, this is our “specialty of the house” and we take pride in carefully aggregating and prepping data before making it available to researchers in industry, healthcare, and academia. Gilles Paubert, Global Head of Cegedim Health Data #realworlddata #rwd #realworldevidence #rwe

RWD and RWE have many advantages for organisations that leverage them to their full potential, but also some disadvantages. One of the biggest drawbacks is the varying acceptance of RWE as “legit” evidence due to the role of unmeasured confounders. In the fall of 2022, PhRMA and BIO conducted a workshop on the subject of unmeasured confounders. A report that captures the main themes and learnings from the workshop has just been published and includes a discussion of novel methodologies for addressing the issue. One of the most interesting aspects of the report is the discussion around fit-for-purpose, research-grade RWD that needs to be intensively curated before being transformed into high-quality, trustworthy evidence generation (pages 11-12 in the report). At Cegedim Health Data, this is our “specialty of the house” and we take pride in carefully aggregating and prepping data before making it available to researchers in industry, healthcare, and academia. #realworlddata #rwd #realworldevidence #rwe

In my latest article for insideBIGDATA, I discuss the intricate process of drug recovery, emphasizing its importance in shaping the future of healthcare. I also explain how #datascience is revolutionizing this field, making it faster and safer! Learn more about it here: https://lnkd.in/e3kmjyM7

Dive into the future of #healthcare with our #newblog post on the Advanced Drug Delivery Systems Market! 💊 Discover the pivotal #trends and factors driving the evolution of this #market. 🚀 Spend your #weekend with us and stay ahead in the realm of healthcare advancements! Read the blog now! 👇

Dive into what's in store for #biopharma and #medtech, and what factors could drive innovation in Deloitte's 2024 Health Care and Life Sciences Outlook article. Read it here: https://bit.ly/48cltwL via Deloitte

🌟 Another Successful Webinar by ISCR! 🌟 We're thrilled to share the success of our recent webinar on "Real World Evidence (RWE) - Crafting a protocol for RWE studies" at the Indian Society for Clinical Research. In this insightful session, we delved deep into the nuances of crafting protocols for Real World Evidence studies, equipping participants with the tools to shape the future of drug development and patient care. Did you miss the webinar? Don't worry! Stay tuned for more groundbreaking updates on upcoming events and resources to stay ahead in the dynamic world of clinical research. A big thank you to all the participants, speakers, and supporters who made this webinar a resounding success! 🙌 #FutureofClinicalResearch #RWE #Webinar #Medical #ISCR #ClinicalResearch #HealthcareInnovation #MedicalScience #DrugDevelopment #PatientCare #ISCR2024 #ResearchLeadership #HealthcareDevelopment #IndianScience #ClinicalTrials #HealthTech #MedicalResearch

The 2024 #DTA Summit in D.C. was fantastic! It was great to hear from so many diverse perspectives working in their own unique ways to foster the development and uptake of digital therapeutics. It's often said in healthcare that there is a tremendous amount of untapped data. And that once we learn to make best use of the data, it can inform decisions that improve health. An interesting consideration is that drugs -- pills, tablets, shots-- don't generate their own data. The act of taking a medicine doesn't generate data by itself. Digital therapeutics do generate data when they are used. As our lives and healthcare become ever more digital, this will be an important distinction, that (I think) makes the case for standalone digital therapies and digital therapies that wrap around pharmaceuticals. Combining medicine with data will improve their function. I learned a lot about the exciting work being done at the federal level to review and authorize these products and various reimbursement mechanisms that are being explored. And discussed how employers are incorporating digital therapeutics into their benefits offerings today for their employees. I enjoyed participating in a panel on 'Enhancing Clinical Impact through Collaboration with Health Plans and PBMs'. My takeaway was that-- while navigating this complex space is difficult and taking place via many nuanced avenues-- in aggregate, a lot of important groundwork is being laid for an important part of the future of healthcare.

This article dissects the nuanced ways in which drug companies may manipulate trial results 🤔 Essential reading for healthcare professionals navigating the complexities of research integrity... What do you think? #ClinicalTrials #ResearchIntegrity #HealthcareEthics